Apolipoprotein CIII: 42 years old and even more interesting

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 31, Issue 3, 2011, Pages 471-473

  Ginsberg, Henry N ^a   Brown, W Virgil ^b  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN C3; CARBOHYDRATE RESPONSE ELEMENT BINDING PROTEIN; FARNESOID X RECEPTOR; GLUCOSE; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PIOGLITAZONE; PROTEOGLYCAN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPOLYSIS; LIPOPROTEIN BLOOD LEVEL; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN METABOLISM; REVIEW;

ANIMALS; APOLIPOPROTEIN C-III; BLOOD GLUCOSE; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; GLUCOSE; HEPATOCYTES; HUMANS; INSULIN; TRANSCRIPTIONAL ACTIVATION; UP-REGULATION;

EID: 79952147414     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.110.221846     Document Type: Review

References (31)

1. Brown WV, Levy RI, Fredrickson DS. Studies of the proteins in human plasma very low density lipoproteins. J Biol Chem. 1969;244:5687-5694.
2. Brown WV, Baginsky ML. Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein. Biochem Biophys Res Commun. 1972;46:376-382.
3. Windler E, Havel RJ. Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceride-rich lipoproteins and their remnants b (Pubitemid 15073727)
4. Norum RA, Lakier JB, Goldstein S, Angel A, Goldberg RB, Block WD, Noffze DK, Dolphin PJ, Edelglass J, Bogorad DD, Alaupovic P. Familial deficiency of apolipoproteins AI and CIII and precocious coronary-artery disease. N Engl J Med. 1982;306:1513-1519. (Pubitemid 12123932)
5. Ginsberg HN, Le N-A, Goldberg IJ, Wang-Iverson P, Gibson JC, Rubinstein A, Norum RA, Brown WV. Apolipoprotein B metabolism in subjects with deficiency of apolipoprotein C-III and A-I: evidence that apolipoprotein C-III inhibits lipoprotein lipase in vivo. J Clin Invest. 1986;78:1287-1295. (Pubitemid 17181567)
6. Ito Y, Azrolan N, O'Connell A, Walsh A, Breslow JL. Hypertriglyceridemia as a result of human apoCIII gene expression in transgenic mice. Science. 1990;249:790-793.
7. Maeda N, Li H, Lee D, Oliver P, Quarfordt SH, Osada J. Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia. J Biol Chem. 1994;269:23610-23616. (Pubitemid 24293564)
8. Klein RL, McHenry MB, Lok KH, Hunter SJ, Le NA, Jenkins AJ, Zheng D, Semler AJ, Brown WV, Lyons TJ, Garvey WT, DCCT/EDIC Research Group. Apolipoprotein C-III protein concentrations and gene polymorphisms in type 1 diabetes: associations with lipoprotein subclasses. Metabolism. 2004;53:1296-1304.
9. Cohn JS, Patterson BW, Uffelman KD, Davignon J, Steiner G. Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensitivity. J Clin Endocrinol Metab. 2004; 89:3949-3955. (Pubitemid 39071498)
10. Rees A, Stocks J, Sharpe CR, Vella MA, Shoulders CC, Katz J, Jowett NI, Baralle FE, Galton DJ. Deoxyribonucleic acid polymorphisms in the apolipoprotein A-I-C-III gene cluster: association with hypertriglyceridemia. J Clin Invest. 1984;76:1090-1095. (Pubitemid 16225605)
11. Chen M, Breslow JL, Li W, Leff T. Transcriptional regulation of the apoC-III gene by insulin in diabetic mice: correlation with changes in plasma triglyceride levels. J Lipid Res. 1994;35:1918-1924. (Pubitemid 24353064)
12. Altomonte J, Cong L, Harbaran S, Richter A, Xu J, Meseck M, Dong HH. Foxo1 mediates insulin action on apoC-III and triglyceride metabolism. J Clin Invest. 2004;114:1493-1503. (Pubitemid 40385579)
13. Hertz R, Bishara-Shieban J, Bar-Tana J. Mode of action of peroxisome proliferators in hypolipidemic drugs. Am Soc Biochem Mol Biol. 1995; 270:13470-13475.
14. Claudel T, Inoue Y, Barbier O, Duran-Sandoval D, Kosykh V, Fruchart J, Gonzalez FJ, Staels B. Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression. Gastroenterology. 2003;125:544-555. (Pubitemid 36929436)
15. Coste H, Rodriguez JC. Orphan nuclear hormone receptor Rev-erb- regulates the human apolipoprotein CIII promoter. J Biol Chem. 2002; 277:27120-27129.
16. Caron S, Verrijken An, Mertens I, Samanez CH, Mautino G, Haas JT, Duran-Sandoval D, Prawitt J, Francque S, Vallez E, Muhr-Tailleux Anne, Berard I, Kuipers F, Kuivenhoven JA, Biddinger SB, Taskinen M-R, Van Gaal L, Staels B. Transcriptional activation of apolipoprotein CIII expression by glucose may contribute to diabetic dyslipidemia. Arterioscler Thromb Vasc Biol. 2011;31:513-519.
17. Li WW, Dammerman MM, Smith JD, Metzger S, Breslow JL, Leff T. Common genetic variation in the promoter of the human apoCIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia. J Clin Invest. 1995;96:2601-2605.
18. Hegele RA, Connelly PW, Hanley AJ, Sun F, Harris SB, Zinman B. Common genomic variations in the APOC3 promoter associated with variation in plasma lipoproteins. Arterioscler Thromb Vasc Biol. 1997; 17:2753-2758. (Pubitemid 28016018)
19. Petersen KF, Defour S, Hariri A, Nelson-Williams C, Foo JN, Dziura J, Lifton RP, Shulman GI. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N Engl J Med. 2010;362:1082-1089.
20. Kozlitina J, Boerwinkle E, Cohen JC, Hobbs HH. Dissociation between APOC3 variants, hepatic triglyceride content, and insulin resistance. Hepatology. 2010. [Epub ahead of print].
21. Cohn JS, Tremblay M, Batal R, Jacques H, Rodriguez C, Steiner G, Mamer O, Davignon J. Increased apoC-III production is a characteristic feature of patients with hypertriglyceridemia. Atherosclerosis. 2004;177: 137-145. (Pubitemid 39361148)
22. Malmendier CL, Lontie JF, Delcroix C, Dubois DY, Magot T, DeRoy L. Apolipoproteins C-II and C-III metabolism in hypertriglyceridemic patients: effect of a drastic triglyceride reduction by combined diet restriction and fenofibrate administration. Atherosclerosis. 1989;77: 139-149. (Pubitemid 19136714)
23. Chan DC, Nguyen MN, Watts GF, Barrett PH. Plasma apolipoprotein C-III transport in centrally obese men: associations with very low-density lipoprotein apolipoprotein B and high-density lipoprotein apolipoprotein A-I metabolism. J Clin Endocrinol Metab. 2008;93:557-564. (Pubitemid 351240831)
24. Sundaram M, Zhong S, Bou Khalil M, Links PH, Zhao Y, Iqbal J, Hussain MM, Parks RJ, Wang Y, Yao Z. Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions. J Lipid Res. 2010;51:150-161.
25. Pavlic M, Valero R, Duez H, Xiao C, Szeto L, Patterson BW, Lewis GF. Triglyceride-rich lipoprotein-associated apolipoprotein C-III production is stimulated by plasma free fatty acids in humans. Arterioscler Thromb Vasc Biol. 2008;28:1660-1665.
26. Sacks FM, Alaupovic P, Moye LA, Cole TG, Sussex B, Stampfer MJ, Pfeffer MA, Braunwald E. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation. 2000;102:1886-1892.
27. Hiukka A, Stahlman M, Pettersson C, Levin M, Adiels M, Teneberg S, Leinonen ES, Mattsson Hulten L, Wiklund O, Oresic M, Olofsson S-O, Taskinen M-R, Ekroos K, Boren J. ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan. Diabetes. 2009;58: 2018-2026.
28. Kawakami A, Aikawa M, Alcaide P, Luscinskas FW, Libby P, Sacks FM. Apolipoprotein C-III induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells. Circulation. 2006;114:681-687. (Pubitemid 44252310)
29. Pollin TI, Damcott CM, Shen H, Ott SH, Shelton J, Horenstein RB, Post W, McLenithan JC, Bielak LF, Peyser PA, Mitchell BD, Miller M, O'Connell JR, Shuldiner AR. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science. 2008;322:1702-1705.
30. Nagashima K, Lopez C, Donovan D, Ngai C, Fontanez N, Bensadoun A, Fruchart-Najib J, Holleran S, Cohn JS, Ramakrishnan R, Ginsberg HN. Effects of the PPARγ agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. J Clin Invest. 2005;115:1323-1332. (Pubitemid 40629052)
31. Chan DC, Nguyen MN, Watts GF, Ooi EM, Barrett PH. Effects of atorvastatin and n-3 fatty acid supplementation on VLDL apolipoprotein C-III kinetics in men with abdominal obesity. Am J Clinical Nutr. 2010;91:900-906.